8-K Announcements
6Material company update
Apr 17, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Mar 23, 2026·SEC
Abbott Laboratories(ABT)Earnings, Financials & Key Ratios
ABT•NYSE
11.6× P/E·Price updated Jun 19, 2026
AboutAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.Show more
- Revenue$41.95B+4.6%
- EBITDA$10.04B+3.8%
- Net Income$13.4B+134.2%
- EPS (Diluted)7.64+133.6%
- Gross Margin50.83%+1.8%
- EBITDA Margin23.94%-0.8%
- Operating Margin16.27%+1.4%
- Net Margin31.95%+123.9%
- ROE30.91%+104.5%
ABT Key Insights
Abbott Laboratories (ABT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Dividend Aristocrat: 43 years of consecutive increases
- ✓Excellent 3Y average ROE of 21.7%
- ✓Strong 5Y profit CAGR of 29.4%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 15.1% free cash flow margin
- ✓Healthy dividend yield of 2.5%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ABT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABT Price & Volume
Abbott Laboratories (ABT) stock price & volume — 10-year historical chart
Loading chart...
ABT Growth Metrics
Abbott Laboratories (ABT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.56%
5 Years5.63%
3 Years-0.88%
TTM6.37%
Profit CAGR
10 Years19.36%
5 Years29.45%
3 Years23.76%
TTM142.36%
EPS CAGR
10 Years17.68%
5 Years29.97%
3 Years24.7%
TTM142.5%
Return on Capital
10 Years9.34%
5 Years11.89%
3 Years11.82%
Last Year10.78%
ABT Recent Earnings
Abbott Laboratories (ABT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 16, 2026Metric
Actual
Est
EPS
$1.15+0.9%
$1.14
Rev
$11.2B+1.5%
$11.0B
Q1 2026
Jan 22, 2026Metric
Actual
Est
EPS
$1.50+0.0%
$1.50
Rev
$11.5B-2.9%
$11.8B
Q4 2025
Oct 15, 2025Metric
Actual
Est
EPS
$1.30+0.0%
$1.30
Rev
$11.4B-0.2%
$11.4B
Q3 2025
Jul 17, 2025Metric
Actual
Est
EPS
$1.26+0.0%
$1.26
Rev
$11.1B+0.5%
$11.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 16, 2026 | $1.15vs $1.14+0.9% | $11.2Bvs $11.0B+1.5% |
| Q1 2026 | Jan 22, 2026 | $1.50vs $1.50+0.0% | $11.5Bvs $11.8B-2.9% |
| Q4 2025 | Oct 15, 2025 | $1.30vs $1.30+0.0% | $11.4Bvs $11.4B-0.2% |
| Q3 2025 | Jul 17, 2025 | $1.26vs $1.26+0.0% | $11.1Bvs $11.1B+0.5% |
Based on last 12 quarters of dataView full earnings history →
ABT Peer Comparison
Abbott Laboratories (ABT) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 EW | 50.37B | 87.36 | 47.74 | 11.55% | 17.64% | 10.35% | 0.07 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare ABT vs Peers
Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABT Income Statement
Abbott Laboratories (ABT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 20.85B | 27.39B | 30.58B | 31.9B | 34.61B | 43.08B | 43.65B | 40.11B | 41.95B | 43.84B |
Revenue Growth % | 2.2% | 31.35% | 11.64% | 4.34% | 8.48% | 24.47% | 1.34% | -8.12% | 4.59% | 6.37% |
Cost of Goods Sold | 9.61B | 14.32B | 14.76B | 15.21B | 17.23B | 19.86B | 21.33B | 20.07B | 20.63B | 20.18B |
COGS % of Revenue | 46.08% | 52.3% | 48.25% | 47.68% | 49.79% | 46.11% | 48.86% | 50.04% | 49.17% | - |
Gross Profit | 11.24B▲ 0% | 13.07B▲ 16.2% | 15.82B▲ 21.1% | 16.69B▲ 5.5% | 17.38B▲ 4.1% | 23.21B▲ 33.6% | 22.32B▼ 3.8% | 20.04B▼ 10.2% | 21.32B▲ 6.4% | 23.67B▲ 0% |
Gross Margin % | 53.92% | 47.7% | 51.75% | 52.32% | 50.21% | 53.89% | 51.14% | 49.96% | 50.83% | 53.98% |
Gross Profit Growth % | 2.59% | 16.2% | 21.1% | 5.5% | 4.1% | 33.59% | -3.84% | -10.24% | 6.43% | - |
Operating Expenses | 8B | 11.09B | 11.98B | 12.1B | 12.09B | 14.01B | 13.96B | 13.6B | 14.47B | 15.91B |
OpEx % of Revenue | 38.34% | 40.5% | 39.18% | 37.93% | 34.92% | 32.53% | 31.98% | 33.91% | 34.5% | - |
Selling, General & Admin | 6.64B | 8.96B | 9.69B | 9.69B | 9.67B | 11.28B | 11.11B | 10.88B | 11.65B | 12.13B |
SG&A % of Revenue | 31.83% | 32.73% | 31.69% | 30.38% | 27.94% | 26.18% | 25.45% | 27.13% | 27.77% | - |
Research & Development | 1.36B | 2.13B | 2.29B | 2.41B | 2.42B | 2.74B | 2.85B | 2.72B | 2.82B | 2.95B |
R&D % of Revenue | 6.51% | 7.78% | 7.48% | 7.55% | 6.99% | 6.36% | 6.53% | 6.78% | 6.73% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M |
Operating Income | 3.25B▲ 0% | 1.97B▼ 39.3% | 3.84B▲ 94.9% | 4.59B▲ 19.4% | 5.29B▲ 15.2% | 9.2B▲ 73.9% | 8.36B▼ 9.1% | 6.43B▼ 23.0% | 6.83B▲ 6.1% | 7.79B▲ 0% |
Operating Margin % | 15.58% | 7.2% | 12.57% | 14.39% | 15.29% | 21.36% | 19.16% | 16.04% | 16.27% | 17.76% |
Operating Income Growth % | 10.17% | -39.3% | 94.93% | 19.43% | 15.25% | 73.88% | -9.11% | -23.04% | 6.06% | - |
EBITDA | 4.6B | 4.99B | 7.12B | 7.61B | 8.62B | 12.74B | 11.63B | 9.68B | 10.04B | 10.92B |
EBITDA Margin % | 22.07% | 18.23% | 23.29% | 23.84% | 24.9% | 29.57% | 26.64% | 24.13% | 23.94% | 24.9% |
EBITDA Growth % | 4.09% | 8.5% | 42.64% | 6.78% | 13.32% | 47.81% | -8.71% | -16.78% | 3.77% | 9.43% |
D&A (Non-Cash Add-back) | 1.35B | 3.02B | 3.28B | 3.01B | 3.33B | 3.54B | 3.27B | 3.24B | 3.22B | 3.13B |
EBIT | 1.72B | 3.11B | 3.6B | 4.89B | 5.68B | 8.62B | 8.62B | 7.36B | 7.62B | 8.67B |
Net Interest Income | -205M | -756M | -624M | -724M | -662M | -367M | -132M | -313M | -259M | -130M |
Interest Income | 99M | 124M | 105M | 94M | 46M | 43M | 183M | 385M | 344M | 321M |
Interest Expense | 304M | 880M | 729M | 818M | 708M | 410M | 315M | 698M | 603M | 451M |
Other Income/Expense | -1.84B | 259M | -971M | -514M | -323M | -989M | -56M | 229M | 188M | 351M |
Pretax Income | 1.41B▲ 0% | 2.23B▲ 57.9% | 2.87B▲ 28.8% | 4.08B▲ 41.9% | 4.97B▲ 21.9% | 8.21B▲ 65.3% | 8.31B▲ 1.2% | 6.66B▼ 19.8% | 7.01B▲ 5.2% | 8.14B▲ 0% |
Pretax Margin % | 6.78% | 8.15% | 9.4% | 12.78% | 14.36% | 19.06% | 19.03% | 16.61% | 16.72% | 18.56% |
Income Tax | 350M | 1.88B | 539M | 390M | 497M | 1.14B | 1.37B | 941M | -6.39B | -5.84B |
Effective Tax Rate % | 24.77% | 84.18% | 18.76% | 9.57% | 10% | 13.88% | 16.53% | 14.12% | -91.1% | -71.75% |
Net Income | 1.4B▲ 0% | 477M▼ 65.9% | 2.37B▲ 396.4% | 3.69B▲ 55.7% | 4.5B▲ 21.9% | 7.07B▲ 57.3% | 6.93B▼ 2.0% | 5.72B▼ 17.5% | 13.4B▲ 134.2% | 13.98B▲ 0% |
Net Margin % | 6.71% | 1.74% | 7.74% | 11.56% | 12.99% | 16.42% | 15.88% | 14.27% | 31.95% | 31.88% |
Net Income Growth % | -68.35% | -65.93% | 396.44% | 55.7% | 21.91% | 57.31% | -1.95% | -17.45% | 134.18% | 142.36% |
Net Income (Continuing) | 1.06B | 353M | 2.33B | 3.69B | 4.47B | 7.07B | 6.93B | 5.72B | 13.4B | 13.98B |
Discontinued Operations | 337M | 124M | 34M | 0 | 24M | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 179M | 201M | 198M | 213M | 219M | 222M | 219M | 224M | 237M | 310M |
EPS (Diluted) | 0.94▲ 0% | 0.27▼ 71.3% | 1.34▲ 396.3% | 2.06▲ 53.7% | 2.50▲ 21.4% | 3.94▲ 57.6% | 3.91▼ 0.8% | 3.27▼ 16.4% | 7.64▲ 133.6% | 7.99▲ 0% |
EPS Growth % | -68.03% | -71.28% | 396.3% | 53.73% | 21.36% | 57.6% | -0.76% | -16.37% | 133.64% | 142.5% |
EPS (Basic) | 0.95 | 0.27 | 1.35 | 2.07 | 2.52 | 3.97 | 3.94 | 3.30 | 7.67 | - |
Diluted Shares Outstanding | 1.48B | 1.75B | 1.77B | 1.78B | 1.79B | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Basic Shares Outstanding | 1.47B | 1.74B | 1.76B | 1.77B | 1.77B | 1.77B | 1.75B | 1.73B | 1.73B | 1.75B |
Dividend Payout Ratio | 109.93% | 387.63% | 83.36% | 61.57% | 56.95% | 45.28% | 47.73% | 62.14% | 28.62% | - |
ABT Balance Sheet
Abbott Laboratories (ABT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 26.78B | 20.15B | 14.63B | 15.67B | 20.44B | 24.24B | 25.22B | 22.67B | 23.66B | 24.84B |
Cash & Short-Term Investments | 18.77B | 9.61B | 4.09B | 4.14B | 7.15B | 10.25B | 10.17B | 7.28B | 7.97B | 7.73B |
Cash Only | 18.62B | 9.41B | 3.84B | 3.86B | 6.84B | 9.8B | 9.88B | 6.9B | 7.62B | 7.51B |
Short-Term Investments | 155M | 203M | 242M | 280M | 310M | 450M | 288M | 383M | 351M | 222M |
Accounts Receivable | 3.25B | 5.25B | 5.18B | 5.42B | 6.41B | 6.49B | 6.22B | 6.57B | 6.92B | 10.4B |
Days Sales Outstanding | 56.85 | 69.95 | 61.86 | 62.07 | 67.65 | 54.97 | 51.99 | 59.74 | 60.25 | 72.6 |
Inventory | 2.43B | 3.6B | 3.8B | 4.32B | 5.01B | 5.16B | 6.17B | 6.57B | 6.19B | 6.71B |
Days Inventory Outstanding | 92.46 | 91.76 | 93.9 | 103.57 | 106.17 | 94.77 | 105.63 | 119.47 | 109.61 | 119.83 |
Other Current Assets | 2.32B | 1.69B | 1.57B | 1.79B | 1.87B | 2.35B | 2.66B | 2.26B | 2.57B | 0 |
Total Non-Current Assets | 28.23B | 56.1B | 52.54B | 52.22B | 52.11B | 50.96B | 49.21B | 50.54B | 57.76B | 59.34B |
Property, Plant & Equipment | 5.71B | 7.61B | 7.56B | 8.97B | 10.13B | 10.11B | 10.28B | 11.28B | 11.73B | 11.5B |
Fixed Asset Turnover | 3.66x | 3.60x | 4.04x | 3.56x | 3.42x | 4.26x | 4.25x | 3.56x | 3.58x | 3.85x |
Goodwill | 7.68B | 24.02B | 23.25B | 23.2B | 23.74B | 23.23B | 22.8B | 23.68B | 23.11B | 23.97B |
Intangible Assets | 4.54B | 21.47B | 18.94B | 17.02B | 14.78B | 12.74B | 10.45B | 8.81B | 6.65B | 5.59B |
Long-Term Investments | 2.95B | 883M | 897M | 931M | 1.03B | 903M | 766M | 799M | 886M | 3.7B |
Other Non-Current Assets | 3.35B | 2.12B | 1.89B | 2.1B | 2.42B | 3.97B | 4.92B | 5.97B | 15.38B | 17.32B |
Total Assets | 55.01B▲ 0% | 76.25B▲ 38.6% | 67.17B▼ 11.9% | 67.89B▲ 1.1% | 72.55B▲ 6.9% | 75.2B▲ 3.6% | 74.44B▼ 1.0% | 73.21B▼ 1.6% | 81.41B▲ 11.2% | 84.18B▲ 0% |
Asset Turnover | 0.38x | 0.36x | 0.46x | 0.47x | 0.48x | 0.57x | 0.59x | 0.55x | 0.52x | 0.53x |
Asset Growth % | 25.02% | 38.61% | -11.9% | 1.06% | 6.87% | 3.65% | -1.01% | -1.64% | 11.2% | 51.85% |
Total Current Liabilities | 6.66B | 8.91B | 9.01B | 10.86B | 11.91B | 13.11B | 15.49B | 13.84B | 14.16B | 14.58B |
Accounts Payable | 1.18B | 2.4B | 2.98B | 3.25B | 3.95B | 4.41B | 4.61B | 4.29B | 4.2B | 4.12B |
Days Payables Outstanding | 44.75 | 61.21 | 73.59 | 78.03 | 83.59 | 81.01 | 78.84 | 78.1 | 74.24 | 76.16 |
Short-Term Debt | 1.32B | 714M | 207M | 1.68B | 461M | 999M | 2.48B | 1.32B | 1.75B | 1.34B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.22B | 4.3B | 4.34B | 4.46B | 5.72B | 5.77B | 6.5B | 6.13B | 5.91B | 0 |
Current Ratio | 4.02x | 2.26x | 1.62x | 1.44x | 1.72x | 1.85x | 1.63x | 1.64x | 1.67x | 1.70x |
Quick Ratio | 3.65x | 1.86x | 1.20x | 1.04x | 1.30x | 1.46x | 1.23x | 1.16x | 1.23x | 1.24x |
Cash Conversion Cycle | 104.56 | 100.5 | 82.17 | 87.6 | 90.23 | 68.73 | 78.79 | 101.11 | 95.63 | 116.28 |
Total Non-Current Liabilities | 27.63B | 36.24B | 27.44B | 25.72B | 27.64B | 26.07B | 22.04B | 20.55B | 19.36B | 18.34B |
Long-Term Debt | 20.68B | 27.21B | 19.36B | 16.66B | 18.53B | 17.3B | 14.52B | 13.6B | 12.63B | 11.6B |
Capital Lease Obligations | 0 | 0 | 0 | 755M | 902M | 956M | 943M | 949M | 896M | 896M |
Deferred Tax Liabilities | 2.7B | 2.01B | 2.06B | 2.13B | 2.15B | 2.07B | 1.84B | 1.22B | 1.37B | 1.37B |
Other Non-Current Liabilities | 4.25B | 7.02B | 6.02B | 6.18B | 6.06B | 5.74B | 4.74B | 4.78B | 4.46B | 6.74B |
Total Liabilities | 31.95B | 45.15B | 36.45B | 36.59B | 39.55B | 39.17B | 37.53B | 34.39B | 33.51B | 32.92B |
Total Debt | 22.01B | 27.92B | 19.57B | 19.1B | 19.89B | 19.25B | 17.95B | 15.87B | 15.28B | 12.94B |
Net Debt | 3.39B | 18.52B | 15.72B | 15.24B | 13.05B | 9.45B | 8.06B | 8.98B | 7.66B | 5.43B |
Debt / Equity | 1.06x | 0.90x | 0.64x | 0.61x | 0.60x | 0.53x | 0.49x | 0.41x | 0.32x | 0.25x |
Debt / EBITDA | 4.78x | 5.59x | 2.75x | 2.51x | 2.31x | 1.51x | 1.54x | 1.64x | 1.52x | 1.19x |
Net Debt / EBITDA | 0.74x | 3.71x | 2.21x | 2.00x | 1.51x | 0.74x | 0.69x | 0.93x | 0.76x | 0.50x |
Interest Coverage | 10.69x | 2.24x | 5.27x | 5.61x | 7.47x | 22.44x | 26.55x | 9.22x | 11.32x | 19.22x |
Total Equity | 20.72B▲ 0% | 31.1B▲ 50.1% | 30.72B▼ 1.2% | 31.3B▲ 1.9% | 33B▲ 5.4% | 36.02B▲ 9.2% | 36.91B▲ 2.4% | 38.83B▲ 5.2% | 47.9B▲ 23.4% | 51.26B▲ 0% |
Equity Growth % | -2.86% | 50.11% | -1.21% | 1.88% | 5.44% | 9.15% | 2.45% | 5.21% | 23.37% | 105.59% |
Book Value per Share | 13.97 | 17.78 | 17.36 | 17.57 | 18.48 | 20.14 | 20.92 | 22.20 | 27.40 | 29.31 |
Total Shareholders' Equity | 20.54B | 30.9B | 30.52B | 31.09B | 32.78B | 35.8B | 36.69B | 38.6B | 47.66B | 50.95B |
Common Stock | 13.03B | 23.21B | 23.51B | 23.85B | 24.14B | 24.47B | 24.71B | 24.87B | 25.15B | 25.41B |
Retained Earnings | 25.57B | 23.98B | 24.56B | 25.85B | 27.63B | 31.53B | 35.26B | 37.55B | 47.26B | 49.1B |
Treasury Stock | -10.79B | -10.22B | -9.96B | -10.15B | -10.04B | -11.82B | -15.23B | -15.98B | -16.84B | -16.88B |
Accumulated OCI | -7.26B | -6.06B | -7.59B | -8.46B | -8.95B | -8.37B | -8.05B | -7.84B | -7.91B | -6.68B |
Minority Interest | 179M | 201M | 198M | 213M | 219M | 222M | 219M | 224M | 237M | 310M |
ABT Cash Flow Statement
Abbott Laboratories (ABT) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 3.2B | 5.57B | 6.3B | 6.14B | 7.9B | 10.53B | 9.58B | 7.26B | 8.56B | 9.12B |
Operating CF Margin % | 15.36% | 20.34% | 20.6% | 19.23% | 22.83% | 24.45% | 21.95% | 18.1% | 20.4% | - |
Operating CF Growth % | 7.99% | 73.9% | 13.11% | -2.6% | 28.76% | 33.31% | -9.04% | -24.21% | 17.86% | 40.12% |
Net Income | 1.38B | 477M | 2.37B | 3.69B | 4.5B | 7.07B | 6.93B | 5.72B | 13.4B | 13.98B |
Depreciation & Amortization | 1.35B | 3.02B | 3.28B | 3.01B | 3.33B | 3.54B | 3.27B | 3.24B | 3.22B | 3.13B |
Stock-Based Compensation | 310M | 406M | 477M | 519M | 546M | 640M | 685M | 644M | 673M | 662M |
Deferred Taxes | 248M | -1.16B | 293M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.43B | 912M | 32M | 247M | 425M | 55M | 215M | 126M | 482M | 432M |
Working Capital Changes | -1.51B | 1.92B | -148M | -1.33B | -892M | -771M | -1.52B | -2.48B | -9.22B | -9.08B |
Change in Receivables | -177M | -207M | -190M | -275M | -924M | -383M | -68M | -356M | -691M | -1.03B |
Change in Inventory | -98M | 249M | -514M | -593M | -493M | -456M | -1.41B | -232M | -58M | 196M |
Change in Payables | -652M | 615M | 747M | 220M | 1.77B | 1.29B | 420M | -760M | 356M | 0 |
Cash from Investing | -248M | -9.62B | -1.36B | -1.81B | -2.21B | -2.01B | -1.74B | -3.13B | -2.34B | -2.38B |
Capital Expenditures | -1.12B | -1.14B | -1.39B | -1.64B | -2.18B | -1.89B | -1.78B | -2.2B | -2.21B | -2.2B |
CapEx % of Revenue | 5.38% | 4.14% | 4.56% | 5.13% | 6.29% | 4.38% | 4.07% | 5.49% | 5.26% | 5.02% |
Acquisitions | -55M | -8.44B | 48M | -122M | 16M | -53M | 48M | -837M | 1M | -55M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 42M | 35M | 48M | 27M | 19M | 26M | 22M | 22M | 9M | -118M |
Cash from Financing | 11.15B | -5.28B | -10.39B | -4.29B | -2.78B | -5.49B | -7.64B | -7.09B | -5.4B | -6.77B |
Debt Issued (Net) | 13.15B | -1.91B | -8.45B | -1.6B | -50M | -248M | -699M | -2.48B | -537M | -2.16B |
Equity Issued (Net) | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -4M |
Dividends Paid | -1.54B | -1.85B | -1.97B | -2.27B | -2.56B | -3.2B | -3.31B | -3.56B | -3.84B | -4.04B |
Share Repurchases | -522M | -827M | -238M | -718M | -403M | -2.3B | -3.79B | -1.23B | -1.29B | -906M |
Other Financing | 53M | -1.05B | 271M | 298M | 234M | 255M | 167M | 167M | 264M | 334M |
Net Change in Cash | 13.62B▲ 0% | -9.21B▼ 167.6% | -5.56B▲ 39.6% | 16M▲ 100.3% | 2.98B▲ 18512.5% | 2.96B▼ 0.6% | 83M▼ 97.2% | -2.99B▼ 3697.6% | 720M▲ 124.1% | -47M▲ 0% |
Free Cash Flow | 2.08B▲ 0% | 4.43B▲ 113.0% | 4.91B▲ 10.6% | 4.5B▼ 8.3% | 5.72B▲ 27.3% | 8.65B▲ 51.1% | 7.8B▼ 9.8% | 5.06B▼ 35.2% | 6.35B▲ 25.5% | 6.92B▲ 0% |
FCF Margin % | 9.98% | 16.19% | 16.04% | 14.1% | 16.54% | 20.08% | 17.88% | 12.61% | 15.14% | 15.78% |
FCF Growth % | 12.18% | 113.02% | 10.62% | -8.32% | 27.26% | 51.08% | -9.76% | -35.17% | 25.54% | 6.65% |
FCF per Share | 1.40 | 2.54 | 2.77 | 2.53 | 3.20 | 4.83 | 4.42 | 2.89 | 3.63 | 3.95 |
FCF Conversion (FCF/Net Income) | 2.29x | 11.68x | 2.66x | 1.66x | 1.76x | 1.49x | 1.38x | 1.27x | 0.64x | 0.49x |
Interest Paid | 181M | 917M | 845M | 677M | 549M | 544M | 563M | 662M | 604M | 0 |
Taxes Paid | 620M | 570M | 740M | 930M | 970M | 1.94B | 1.86B | 1.48B | 1.72B | 0 |
ABT Key Ratios
Abbott Laboratories (ABT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 6.66% | 1.84% | 7.66% | 11.89% | 13.98% | 20.49% | 19.01% | 15.11% | 30.91% | 27.26% |
Return on Invested Capital (ROIC) | 9.86% | 4.01% | 6% | 7.41% | 8.57% | 15.08% | 13.87% | 10.4% | 9.9% | 10.37% |
Gross Margin | 53.92% | 47.7% | 51.75% | 52.32% | 50.21% | 53.89% | 51.14% | 49.96% | 50.83% | 53.98% |
Net Margin | 6.71% | 1.74% | 7.74% | 11.56% | 12.99% | 16.42% | 15.88% | 14.27% | 31.95% | 31.88% |
Debt / Equity | 1.06x | 0.90x | 0.64x | 0.61x | 0.60x | 0.53x | 0.49x | 0.41x | 0.32x | 0.25x |
Interest Coverage | 10.69x | 2.24x | 5.27x | 5.61x | 7.47x | 22.44x | 26.55x | 9.22x | 11.32x | 19.22x |
FCF Conversion | 2.29x | 11.68x | 2.66x | 1.66x | 1.76x | 1.49x | 1.38x | 1.27x | 0.64x | 0.49x |
Revenue Growth | 2.2% | 31.35% | 11.64% | 4.34% | 8.48% | 24.47% | 1.34% | -8.12% | 4.59% | 6.37% |
Related:ABT Dividend History·ABT Revenue History·ABT Price History·ABT P/E History·ABT Financial Ratios·ABT Institutional Holders
ABT SEC Filings & Documents
Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABT Frequently Asked Questions
Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Abbott Laboratories (ABT) reported $43.84B in revenue for fiscal year 2024. This represents a 338% increase from $10.01B in 1995.
Abbott Laboratories (ABT) grew revenue by 4.6% over the past year. Growth has been modest.
Yes, Abbott Laboratories (ABT) is profitable, generating $13.98B in net income for fiscal year 2024 (31.9% net margin).
Dividend & Returns
Yes, Abbott Laboratories (ABT) pays a dividend with a yield of 2.48%. This makes it attractive for income-focused investors.
Abbott Laboratories (ABT) has a return on equity (ROE) of 30.9%. This is excellent, indicating efficient use of shareholder capital.
Abbott Laboratories (ABT) generated $6.92B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.